We still pay for Agile (presumably mostly paid off now) and the EVT801 phase 1 trial. Other biotechs with a number of trials similar to Kazia have yearly cash burn over $100 million.
Week 45 Wrap: Combat sports usher in Trump 2.0 – or is it male insecurity?; RBA boring; Propane suggests China alive
MKT The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint
